Synonyms: AZD2014; AZD2014; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Benzamide, 3-(2,4-bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-; Vistusertib [INN]; Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-; Vistusertib [USAN]; 1009298-59-2; Vistusertib (JAN/INN); MLS006011011; SCHEMBL290672; GTPL7699; AOB3574; DTXSID20143584; EX-A155; SYN1167; BCP05748; KS-000000YA; Vistusertib; BDBM50429701; MFCD22628784; s2783; ZINC59258964; AKOS024464879; BCP9000362; CS-0701; DB11925; QC-4554; SB16565; AZD-2014; NCGC00346698-11; 4CA-0223; AC-28425; AS-16302; BC600520; HY-15247; SC-62590; SMR004702809; AB0095803; SW219704-1; AZD 2014; X3569; D10887; W-5962; J-000268; 3-[2,4-Bis-[(3S)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; D0Z2UQ; A8373; Vistusertib, 98%, a novel mTOR inhibitor - 100MG 100mg; UNII-0BSC3P4H5X; vistusertib (AZD2014); 0BSC3P4H5X; cc-551;